

Department of Dermatology

Publication and Project List (2019 onwards)

Dr Nilay Kanti Das

Publication

1. Bhattacharya T, Datta J, Sen I, Patra AC, Roy S, Sarkar AP, **Das NK**. Perception among the sufferers of recalcitrant dermatophytosis regarding its causation, prevention, care-seeking behaviour and their personal hygiene: A qualitative research. *Indian Dermatol Online J* 2022;13:52-9
2. Patra AC, Sil A, Ahmed SS, Rahaman S, Mondal N, Roy S, Datta A, Kaliyadan F, Panda S, Setia MS, Dogra S, Khandpur S, Hazra A, **Das NK**. Effectiveness and safety of 0.5% timolol solution in the treatment of pyogenic granuloma: A randomized, double-blind and placebo-controlled study. *Indian J Dermatol Venereol Leprol.* 2021 Oct 15;1-9. doi: 10.25259/IJDVL_565_20. Epub ahead of print. PMID: 34672473.
3. A, Rahaman S, Mondal N, Ahmed SS, Tarafdar D, Patra AC, Roy S, **Das NK**. An investigator-blind randomized controlled trial comparing effectiveness, safety of levocetirizine and bepotastine in chronic urticaria. *Indian J Dermatol* 2021;66:472-8
4. Ghosh P, Roy P, Chaudhuri SJ, **Das NK**. Epidemiology of post-kala-azar dermal leishmaniasis. *Indian J Dermatol* 2021;66:12-23
5. Kumar P, Chatterjee M, **Das NK**. Post kala-azar dermal leishmaniasis: Clinical features and differential diagnosis. *Indian J Dermatol* 2021;66:24-33
6. Datta A, Podder I, Das A, Sil A, **Das NK**. Therapeutic modalities in post kala-azar dermal leishmaniasis: A systematic review of the effectiveness and safety of the treatment options. *Indian J Dermatol* 2021;66:34-43
7. **Das NK**. Post kala-azar dermal leishmaniasis. *Indian J Dermatol* 2020;65:450-1
8. Datta A, Chandra S, Saha A, Sil A, **Das NK**. Exploring the safety and effectiveness of subcutaneous autologous serum therapy versus conventional intramuscular autologous serum therapy in chronic urticaria: An observer-blind, randomized, controlled study. *Ind J Dermatol Venereol Leprol* 2020; 86:632-42.
9. Roy S, Patra AC, Bandyopadhyay D, Datta PK, **Das NK**. Comparative evaluation of Acid fast bacilli positivity by slit skin smear, bacterial index of granuloma in paucibacillary and multibacillary leprosy types as per WHO operational classification. *Indian J Lepr* 2020; 92:1-9.
10. Saha S, Patra AC, Gowda SP, Mondal N, Rahaman S, Ahmed SKS, Debbarma S, Vitthal KPK, Sarkar S, Sil A, **Das NK**. Effectiveness and safety of autologous platelet-rich plasma therapy with total contact casting versus total contact casting alone in treatment of trophic ulcer in leprosy: An observer-blind, randomized controlled trial. *Indian J Dermatol Venereol Leprol.* 2020 May- Jun;86(3):262-271.
11. Moulik S, Sengupta R, Dighal A, Sardar B, Saha B, **Das NK**, Chatterjee M. Identification of atypical dermal leishmaniasis resolved by restriction fragment length polymorphism. *Indian J Dermatol Venereol Leprol.* 2020 Jan- Feb;86(1):45-49.
12. Dighal A, Mukhopadhyay D, Sengupta R, Moulik S, Mukherjee S, Roy S, Chaudhuri SJ, **Das NK**, Chatterjee M. Iron trafficking in patients with Indian Post kala-azar dermal leishmaniasis. *PLoS Negl Trop Dis.* 2020 Feb 5;14(2):e0007991. doi: 10.1371/journal.pntd.0007991. PMID: 32023254
13. Sil A, Betkerur J, **Das NK**. P-Value Demystified. *Indian Dermatol Online J.* 2019 Nov 1;10(6):745-750.

14. Sil A, Kumar P, Kumar R, **Das NK**. Selection of Control, Randomization, Blinding, and Allocation Concealment. *Indian Dermatol Online J*. 2019 Aug 28;10(5):601-605.
15. Chandra S, Sil A, Datta A, Pal S, **Das NK**. A double-blind, randomized controlled trial to compare the effectiveness and safety of purified protein derivative of tuberculin antigen with Mycobacterium w vaccine in the treatment of multiple viral warts. *Indian J Dermatol Venereol Leprol*. 2019 Jul-Aug;85(4):355-366.
16. Sett A, Pradhan S, Sancheti K, Basu D, Datta A, Biswas L, Das S, Pal SK, Gupta N, Sil A, **Das NK**. Effectiveness and Safety of Metformin versus Canthex™ in Patients with Acanthosis Nigricans: A Randomized, Double-blind Controlled Trial. *Indian J Dermatol*. 2019 Mar-Apr;64(2):115-121.
17. Sengupta R, Mukherjee S, Moulik S, Mitra S, Chaudhuri SJ, **Das NK**, Chatterjee U, Chatterjee M. In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis. *Int J Parasitol Drugs Drug Resist*. 2019 Dec;11:166-176.
18. Chandra S, Sancheti K, Podder I, Das A, Sarkar TK, Chowdhury M, Sil A, Bhattacharya S, **Das NK**. A Randomized, Double-blind Study of Amorolfine 5% Nail Lacquer with Oral Fluconazole Compared with Oral Fluconazole Alone in the Treatment of Fingernail Onychomycosis. *Indian J Dermatol*. 2019 Jul- Aug;64(4):253-260.
19. Sengupta R, Chaudhuri SJ, Moulik S, Ghosh MK, Saha B, **Das NK**, Chatterjee M. Active surveillance identified a neglected burden of macular cases of Post Kala-azar Dermal Leishmaniasis in West Bengal. *PLoS Negl Trop Dis*. 2019 Mar 11;13(3):e0007249.

Editor of Book

1. **Das NK**, Savitha M, Mohta A, Sil A, Dupta D, editors. *IADVL Research Compendium*. CBS Publishers and Distributors Pvt Ltd. New Delhi 2022. **ISBN: 978-93-90619-96-2**

Author of Chapters in Books

1. **Das NK**, Sil A. Ethics in Biomedical Research. In: **Das NK**, Savitha M, Mohta A, Sil A, Dupta D, editors. *IADVL Research Compendium*. CBS Publishers and Distributors Pvt Ltd. New Delhi 2022. P 176-86.
2. Kumar P, **Das NK**. Bacterial skin infection. In: Sarma N, Chakraborty S, Chowdhury J, editors. *Skin: Clinical Dermatology*. New Delhui. Jaypee Brotehrs Medical Publisher (P) Ltd. 2019. P 417-29.

Project

Planned

1. A study to evaluate the antifungal property of Nano Zinc oxide against dermatophytes and in vivo dermal pharmacokinetics and subacute dermal toxicity
2. A study exploring the perception and attitude towards healthcare seeking behavior along with stigma in relation to Post kala-azar Dermal Leishmaniasis in West Bengal, India
3. Evaluation of effectiveness, safety, and tolerability of high frequency phonophoresis using 1% methotrexate gel as an add on therapy to topical clobetasol ointment&1% coal tar in treatment of palmoplantar psoriasis: an institution based double blind randomised controlled trial
4. Immunological analysis of serum cytokines for evaluating role of potential host factors as markers of susceptibility and predictors of severity of leprosy in West Bengal, India
5. Effect of oral Tofacitinib with NBUVB versus NBUVB alone to produce improvement in clinical and molecular marker of melanogenesis in unstable vitiligo: Investigator blind, randomized controlled trial.

Ongoing

| | |
|-------------------------|---|
| CTRI/2021/09/03 6335 | An assessor-blind, phase III multi-centric, randomized controlled trial to evaluate the immunotherapeutic efficacy of Mycobacterium Indicus Pranii (MIP) vaccine, Bacillus Calmette Guerin (BCG) vaccine as an adjunct to chemotherapy in Multibacillary (MB) patients of leprosy |
| CTRI/2021/09/03 6230 | Effectiveness and safety of topical platelet-rich-fibrin-membrane with plaster-cast versus injectable platelet-rich-plasma therapy with plaster-cast in trophic ulcer due to leprosy: randomised-controlled-trial |
| CTRI/2020/08/02 7352 | Usefulness and safety Of Cryotherapy versus Bleomycin injection in the treatment of localised keloids. |

Completed

| | |
|-------------------------|---|
| CTRI/2019/07/02 0345 | Usefulness and safety of ultra violet light with steroid cream versus antimalarial tablet with steroid cream in patients of vitiligo. |
| CTRI/2019/09/02 1049 | Does addition of Tazarotene cream help in controlling fungal infections of skin over and above two antifungal medicines? |

Dr Chinmay Kar

Publication

1. **Kar C**, Saha P, Chakrabarti N, Sarkar P, Histopathological study of post kala-azar dermal leishmaniasis and its importance for diagnosis in a peripheral tertiary institution. *IP Indian J Clin Exp Dermatol* 2019;5(1):9-15.
2. **Kar C**, Sardar SK. Pattern of pathological cutaneous lesions of neonates in neonatal care unit of a peripheral tertiary institution in West Bengal. *Indian J Paediatr Dermatol* 2020;21:22-30
3. Dutta A, De A, Das S, Banerjee S, **Kar C**, Dhar S. A cross-sectional evaluation of the usefulness of the minor features of hanifin and rajka diagnostic criteria for the diagnosis of atopic dermatitis in the pediatric population. *Indian J Dermatol* 2021;66:583-90

Dr Indrashis Podder

Publication

1. **Podder I**, Jaiswal S, Das A. Dietary strategies for chronic spontaneous urticaria: an evidence-based review. *Int J Dermatol*. 2021 Nov 26. doi: 10.1111/ijd.15988. Epub ahead of print. PMID: 34826140.
2. **Podder I**, Mondal H, Kroupouzou G. Nocturnal pruritus and sleep disturbance associated with dermatologic disorders in adult patients. *International Journal of Women's Dermatology*. 2021 Mar 3.[Ahead of print]
3. Mohanty S, **Podder I**, Ghosh A, Chowdhury SN, Bandyopadhyay D. Clinico-demographic profile of patients with foot dermatitis: A cross-sectional study with special reference to patch test results. *Indian Journal of Dermatology*. 2020;65:377.
4. **Podder I**, Das A, Ghosh S, Biswas D, Sengupta S, Chowdhury SN. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial. *Dermatologic Therapy*. 2020;33:e13946.
5. Agarwal A, Das A, Hassanandani T, **Podder I**, Panda M. Topical pramoxine in chronic pruritus: Where do we stand?. *Indian Journal of Dermatology*. 2021 ;66:576.
6. Das K, Daveluy S, Kroupouzou G, Agarwal K, **Podder I**, Farnbach K et al. Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa. *Journal of Clinical Medicine*. 2022;11:670.
7. Agarwal K, **Podder I**, Cockerell CJ, Kassir M, Grabbe S, Goldust M. Update on diagnosis and treatment of actinic keratosis. *Dermatological Reviews*. [Ahead of print]
8. Das A, Sil A, Fatima F, **Podder I**, Jafferany M. Impact of chronic and recurrent dermatophytosis on quality of life and psychologic morbidity-a cross-sectional study. *J Cosmet Dermatol*. 2021 Dec 13. [Ahead of print]
9. Agarwal K, Barua S, **Podder I**. Knowledge, attitude, practice and perception towards effects of sun exposure and sunscreen use among medical and non-medical university students: A cross-sectional, comparative study from eastern India. *Australas J Dermatol*. 2021 Dec 21. [Epub ahead of print.]
10. Datta D, Sarkar R, **Podder I**. Parental Stress and Quality of Life in Chronic Childhood Dermatoses: A Review. *J Clin Aesthet Dermatol*. 2021;14(9 Suppl 1):S19-S23.
11. Saha I, **Podder I**, Chowdhury SN, Bhattacharya S. Clinico-mycological profile of treatment-naïve, chronic, recurrent and steroid-modified dermatophytosis at a tertiary care centre in Eastern India: An institution-based cross-sectional study. *Indian Dermatol Online J* 2021;12:714-21.
12. Agarwal K, **Podder I**, Sarkar R. Pigmented transverse nasal band: A review. *Indian J Dermatol Venereol Leprol*. 2021 Aug 5:1-4. Epub ahead of print. PMID: 34379951.
13. Mintoff D, Chatterjee M, **Podder I**, Shipman A, Das A. Clinical dermatology and COVID-19 pandemic: Narrative review. *Indian J Dermatol*. 2021;66:246-55

14. Pradhan S, **Podder I**, Chowdhury SN, Banerjee G, Bandyopadhyay D. Clinico-Epidemiological Spectrum of Childhood Leprosy in Post-Elimination Era: A Multi-Centre, Cross-Sectional Study from West Bengal. *Indian J Lepr.* 2021;93:193-202.
15. **Podder I**, Agarwal K, Anurag A. Metabolic status, obesity, and quality of life in patients with acne vulgaris: A cross-sectional case-control study. *Indian Journal of Dermatology.* 2021;66:223.
16. Saha M, **Podder I**, Das A. Skin damage induced by enhanced protective measures in frontline doctors during Covid-19 pandemic: A web-based descriptive study. *Indian Journal of Dermatology.* 2021;66:145.
17. Bhardwaj P, Basu D, **Podder I**, Gharami RC. Clinico-epidemiological profile of childhood alopecia areata along with dermoscopic correlation: A cross-section, observational study. *Indian Dermatology Online Journal.* 2021;12:250.
18. Hasan R, Agarwal K, **Podder I**, Misitzis A, Schwartz RA, Wollina U, Lotti T, Grabbe S, Goldust M. Simvastatin in vitiligo: an update with recent review of the literature. *International journal of dermatology.* 2021 Feb 7.[Ahead of print]
19. Datta A, **Podder I**, Das A, Sil A, Das NK. Therapeutic modalities in post kala-azar dermal leishmaniasis: A systematic review of the effectiveness and safety of the treatment options. *Indian Journal of Dermatology.* 2021;66:34.
20. Gayen R, **Podder I**, Chakraborty I, Chowdhury SN. Sex hormones, metabolic status, and obesity in female patients with acne vulgaris along with clinical correlation: An observational cross-sectional study. *Indian Journal of Dermatology.* 2021;66:60.
21. Sarkar R, **Podder I**, Jagadeesan S. Rosacea in skin of color: A comprehensive review. *Indian Journal of Dermatology, Venereology, and Leprology.* 2020;86:611.
22. Agarwal K, **Podder I**, Bandyopadhyay A, Chowdhury SN. Michelin tire baby syndrome with dermal sclerosis: A novel association. *Indian Journal of Dermatology.* 2020;65:538.
23. **Podder I**, Sadoughifar R, Goldust M, Torello L. Rationale and utility of sub-therapeutic/low dose cytokines and growth factors in dermatology: an overview. *Russian Journal of Skin and Venereal Diseases.* 2020;23:293-302.
24. Das A, Fatima F, Sil A, **Podder I**, Jafferany M. Therapeutic management of psychological morbidity and impaired quality of life in patients with persistent dermatophytoses. *Dermatologic Therapy.* 2020;33:e14124.
25. Goldust M, Agarwal K, **Podder I**, Navarini AA. Skin cancer and COVID-19. *Dermatologic Therapy.* 2020 Jan 1.
26. Kassir M, **Podder I**, Olisova OY, Lomonosov KM, Lotti T, Goldust M. Melanoma: A silver lining in the black cloud of COVID-19. *Dermatologic Therapy.* 2020:e14070.
27. **Podder I**, Agarwal K, Datta S. Comparative analysis of perceived stress in dermatologists and other physicians during national lock-down and COVID-19 pandemic with exploration of possible risk factors: A web-based cross-sectional study from Eastern India. *Dermatologic Therapy.* 2020;33:e13788.
28. Goldust M, Agarwal K, Kroumpouzou G, Jafferany M, Lotti T, **Podder I**. Mental health status of dermatologists during the COVID-19 pandemic; a technology-based therapy. *Dermatologic Therapy.* 2020 Jul 1.
29. Lotti T, Agarwal K, **Podder I**, Satolli F, Kassir M, Schwartz RA, Wollina U, Grabbe S, Navarini AA, Mueller SM, Goldust M. Safety of the current drug treatments for vitiligo. *Expert opinion on drug safety.* 2020;19:499-511.
30. Agarwal K, **Podder I**, Kassir M, Vojvodic A, Schwartz RA, Wollina U, Valle Y, Lotti T, Rokni GR, Grabbe S, Goldust M. Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature. *Dermatologic therapy.* 2020;33:e13215.
31. **Podder I**, Chowdhury S. Sturge-webber syndrome: An uncommon entity. *Ind J Med Res.* 2020;152:73.
32. Chandra S, Sancheti K, **Podder I**, Das A, Sarkar TK, Chowdhury M, Sil A, Bhattacharya S, Das NK. A randomized, double-blind study of amorolfine 5% nail lacquer with oral fluconazole compared with oral fluconazole alone in the treatment of fingernail onychomycosis. *Indian journal of dermatology.* 2019;64:253.

Project

| Title of study | Details |
|--|--|
| A Prospective, multi-centre, randomized, double-blind, two-arm, parallel group, active control, comparative clinical study to evaluate efficacy and safety of R-TPR-046/ Stelara® in patients with moderate to severe plaque psoriasis | Phase III |
| A Phase III, Multi-centre, Double Blind, Comparative, Randomized, Prospective, Parallel Study to Evaluate the Efficacy and Safety of Naftifine Hydrochloride gel 2% in patients with Interdigital Tinea Pedis | Phase III |
| Effectiveness, Safety and Tolerability of Standard dose of Bilastine and Up-dosed Bilastine for the uncontrolled Chronic Spontaneous Urticaria | Dose-determining trial (thesis Pharmacology PGT) |
| A Multicentric, Randomized, Prospective, Double-blind, Parallel-group, Comparative and Phase III Clinical Study to evaluate the Efficacy and Safety of Ozenoxacin Lotion 2% w/v in the Treatment of Patients with Acne Vulgaris | Phase III |
| A prospective, randomized, two-arm, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Amorolfine lotion 0.25% w/v as compared to Amorolfine cream 0.25% w/w in patients with superficial fungal infection of the skin | Phase III, Completed |